Anticipated as well as recently launched global Bioresorbable Coronary Stents Market size will trigger a revenue increase to USD 247 million by 2025. At a CAGR of 15% according to a new report by Grand View Research, Inc., better device attributes of second-generation coronary stents will provide the ascending push to this market.
Bioresorbable stents are intended majorly for the
young adult population, whereby these individuals are enabled with a normal
functioning artery following complete resorption of the dissolvable
devices.Lifestyle diseases and prevalence of associated risk factors underpin
the growth in atherosclerosis-related cardiac events. This drives the global
disease prevalence in young adults as well as the high volume of elective
Percutaneous Coronary Interventions (PCI).
What sets the second-generation bioresorbable coronary
stents apart? – Learning from past mistakes, manufacturers have developed new
generation bioresorbable with thinner strut thicknesses, faster resorption
times, and better radial force. Amaranth, with a single-minded focus on strut thickness,
has developed three such devices. Each with a thinner strut. The latest,
Magnitude boasts of 100 microns.
Another factor providing a fillip to this market is
the less-invasive nature of PCIs as compared to coronary artery bypass
grafting, resulting in their high elective procedure volume. In most parts of
the world, lack of auditing to check inappropriate surgeries drives the number
of coronary stenting procedures. Hence, this market is expected to witness
growth due to the high volume of elective PCI, particularly in APAC and Europe.
Request a sample copy or view summary of this report@
http://www.grandviewresearch.com/industry-analysis/bioresorbable-coronary-stents-market
Further Key Findings From the
Study Suggest:
- Europe
region is the major contributor for the bioresorbable stents market in
2016. Subsequent to withdrawal of the bioresorbable Absorb BVS, emergence
of CE-approved bioresorbable stents hold strong growth prospects for
greater sales in the member countries.
- APAC
follows Europe with almost 30% segment share and is expected to record the
fastest growth in the future
- Absorb
BVS, among the key brands, engendered the highest sales revenue in 2016,
while Absorb 2nd generation device will supersede the
sales of its rival devices toward the end of the forecast period
- North
America trails behind as the smallest revenue generator against leading
counterparts, Europe and APAC, in this bioresorbable coronary stents
market. Downfall of Abbott’s Absorb BVS, the only approved FDA device, is
the underlying reason for the small segment share in the U.S. region.
- Key
players in this space include BIOTRONIK, Meril Lifesciences Pvt. Ltd.,
Abbott, Elixir Medical Corporation, REVA Medical, Arterial Remodeling
Technologies, and Amaranth Medical
- Strategic
efforts undertaken by the companies to gain a higher market share center
on bioresorbable coronary stents development. Companies targeting the
clinical pipeline have developed second-generation bioresorbable products
with better design specifications, such as devices with thinner strut
thicknesses and faster absorption rates that gain comparability with the
gold standard, drug-eluting metallic stents.
About Us:
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research reports,
customized research reports, and consulting services. To help clients make
informed business decisions, the company offers market intelligence studies
ensuring relevant and fact-based research across a range of industries
including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment